Antisense & RNAi Therapeutics Market Synopsis

Antisense And RNAi Therapeutics Market size was valued at USD 4.4 billion in 2023 and and is Projected to Reach USD 9.65 Billion by 2032, Growing at a CAGR of 18.2% From 2024-2032

Antisense and RNA interference (RNAi) therapeutics can be described as a number of revolutionary treatment methods that incorporate synthetic oligonucleotides and RNA molecules to regulate the expression of a particular gene post-transcription. Antisense therapies work with short strands of nucleic acids that are complementary to the target mRNA sequences that are involved in diseases at genetic level including genetic disorder and cancers. In contrast, RNAi therapeutics utilize the inherent cellular process of RNA interference in which small interfering RNAs (siRNAs) or microRNAs (miRNAs) are delivered to reduce the expression of specific mRNAs or degrade them completely open up a vast platform for the treatment of viral diseases and a myriad other diseases. This market is relatively new and has strong growth potential due to the growth in molecular biology, higher spending on industry research and development, and greater knowledge of genetic treatments, helping to increase pipelines and ant accurate medicine that may introduce major innovations.

• The Antisense & RNA Interference (RNAi) therapeutics market has turned out as a crucial segment in the pharmaceutical industry by acquiring the innovation of molecular biology and genetic research. ASOs and RNA interference represent new technologies curved on specific genes and pathways and has therapeutic implications in several genetic disorders and diseases, including cancers, neurological disorders, and viral infections. The market is also experiencing growth because of allowed pipeline products, and drugs that are increasingly in clinical phases. Increased incidences of chronic ailments coupled with an increasing need for customized treatment is the foundation for enhancements in this sector’s research and development, which leads to renewed therapeutic solutions and treatments.
• This is due to the fact it encompasses a wide diverse application in genetic disorders treatment, infectious diseases, and different types of cancer. Since RNAi and antisense technologies work on the principal of silencing particular genes and with increasing success in doing so, they hold bright light at the end of the tunnel for situations earlier thought to be beyond cure. The improvements in carriers like lipid nanoparticles and conjugated systems are helping to increase the effectivity and selectivity of these treatments, and thereby extending its utility. Also, partnerships between biotech entities and academic organisations have provided a fillip to innovation as the latter are delivering novel and effective therapeutic assets.
• Regionally, North America is the largest consumer for antisense & RNAi therapeutics due to the increased base for research, expenditure on healthcare and a higher incidence of genetic diseases. Europe too holds promising trends for market expansion and improvement of the legal base on market-oriented regulation and enhancing investments on biotechnology. The Asia-Pacific region appears that is likely to gain significant prominence in the coming years primarily due to increase in research and development expenditure and escalating awareness of genetic treatment. In total, the Antisense & RNAi therapeutics market is expected to grow at an astounding rate, bring innovation to many therapeutic areas while providing shareholders significant value, thus positioning it as a major focal point for those involved in the biopharmaceutical industry.

Antisense & RNAi Therapeutics Market Trend Analysis

Advancements in Precision Medicine and Delivery Mechanisms in Antisense & RNAi Therapeutics Market

• Currently the nascent antisense and RNA interference (RNAi) therapeutics market has seen one of the most prominent and continued shifts towards precision medicine. contact lens approach enables one to design individual specific therapeutic interventions based on an individual’s genetic makeup and improve therapeutic efficiency. Thus, genetic information will help healthcare providers, to prescribe patients certain therapies that are most effective in treating disease characteristics. This phenomenon is especially useful for chronic diseases like cancer, genetic disorders, and viral diseases because the conventional ‘mass solution’ prove to be inadequate. To explore ASOs and siRNAs as tools for targeted therapy and therapeutics, companies are spending a lot of money on research and development. These new approaches focus on modulating for the most part, those faulty genes associated with disease thereby paving the way for targeted therapy which will indeed be a game changer for most patients.
• Apart from precision medicine the delivery mechanisms & formulations are another major growth sectors affecting the market. The major limitations on RNA-based therapy including stability, bioavailability, and off-target effects are increasingly being tackled by new delivery systems like lipid nanoparticle and polymer based systems. These technologies increase the therapeutic index and promote better interactions between ASOs and siRNAs with the target tissues thereby expanding their therapeutic value. In addition, the cross industry approach and partnership between small biotech companies and large pharmaceutical firms along with academic organizations are enhancing the research and market entry of these treatments. RNA targeting via antisense and RNAi is also showing positive regulatory attitudes as more agencies around the world approve RNA based therapeutics and continue to have active pipelines with numerous clinical trials ongoing, a clear indication that antisense and RNAi based therapeuticals will offer hope to many patients suffering from hitherto untreatable diseases.

Collaborations and Innovations in Delivery Mechanisms in Antisense & RNAi Therapeutics Market

• The another emerging trend noticed in the antisense and RNA interference (RNAi) therapeutics market is the increase in the number of alliances and affiliations between the biotech companies, the pharmaceutical concerns and the academic bodies. Such collaborations are entered into with a view of assembling skills, tools and technologies, to enhance the rate of coming up with new drugs. As these collaborations bring experts and resource together, difficult disease may be solved in a faster manner since existing knowledge and unique skills may be merged to allow for quicker research and development. This trend simply shows how improved idea sharing and collaboration by various researchers across specializations are vital in a growing area of study, namely RNA-based therapies, given the persistence of barriers to innovation.
• Not only does increased partnership continue to grow but also the delivery systems continue to improve the effectiveness and reliability of RNA-based treatments. Advanced delivering systems like lipid nanoparticles and polymer conjugates are used in this context to enhance the delivery of ASOs and siRNAs, backbones of such therapies where issues like stability, solubility, and off targeting have been traditionally problematic. This growing approval of RNA-based therapies by regulatory authorities also supports the market trend of constant growth. In addition, increasing funding for clinical trials show high optimism in disease modifying role of these therapies. With the opening of new RNA biology era potent antisense and RNAi therapeutics market promises an unprecedented increase in disease and condition treatment possibilities.

Antisense & RNAi Therapeutics Market Segment Analysis:

Antisense & RNAi Therapeutics Market Segmented based on By Indication, By Technology, By Route of administration, By End Use and By Distribution Channel

By  Indication, Oncology segment is expected to dominate the market during the forecast period

• The oncology segment covers numerous forms of cancer among them are breast cancer, lung cancer, prostate cancer and colorectal cancer among other diseases. These malignancies are insidious due to the complexity of their, and high inter-treatment heterogeneity. The targeted therapies are relatively new and are part of a personalized medicine approach in cancer, which has been supplemented by RNA interference (RNAi) and antisense RNA technology. Such therapies are quite novel and hope to target certain genes responsible for tumor characteristics so as to offer more personalized treatment with specific reference to the genotype of a particular patient and the phenotype of the tumor.
• Apart from increasing the selectivity of treatment, these technologies are expected to reduce the toxic effects normally associated with conventional therapies such as chemotherapy and radiation. As distinct from chemotherapy and radiotherapy, RNAi and antisense therapies have a precise potent for the molecular approaches that govern cancer and can inhibit the creation of proteins that act as signals for cell proliferation and survival. For this reason, patients can receive better results such as higher rates of response, as well as longer survival periods. This move in the cancer treatment system just show the need to continue research and development in oncology; the world is still in dire need of more advancements in treatment of cancer, and innovative treatment in cancer is absolutely have great potentials of changing the management of cancer.

By Distribution Channel, Hospital Pharmacy segment held the largest share in 2023

• Hospital pharmacy plays an important role in hospital system, which is responsible in particular for the rational use and delivery of medicines within a hospital. Their primary function is to ensure that patient requires right medication and treatment especially the chronic cases or complicated cases like oncology or intensive care unit I Cunning. This entails detailed knowledge of each patient’s medical condition, antecedents, and planned management, together with information on various medications and potential interactions to make rational choices about programmes of treatment. In the broader aspect, hospital pharmacy has the responsibility of providing information to the drug users and providers in the hospital regarding proper use of drugs, possible side effects and any other possible alternatives which make the patient safer and the therapeutic outcomes better.
• Hospital and health-system pharmacy is another model of positioning that is characterised by significant emphasis on the sterile compounding that prevents contamination. This is more important in injectable preparations, solutions for intravenous use and other sterile preparations used in hospitals and other inpatient care facilities. Additionally, the hospital pharmacists are responsible for ordering, receiving, storing, dispunging and controlling mediations that are often complicated treatment regimens of multiple medications specific to patient needs. This includes assesment of efficacy and safety, dosage modifications and measuring up to regulatory requirements. In addition to objective aspects influenced by hospital pharmacists, such as the rational storage and distribution of medicines, the staff’s professionalism helps to focus on the problem of enhancing the overall patient care in a hospital setting.

Antisense & RNAi Therapeutics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• Among the regions of the world, North America dominates the antisense and RNAi therapeutics market and this is primarily attributed to increased research in the field of antisense and RNAi therapeutics and a very huge spending on healthcare. The area is comprised numerous large-scale pharma and biotech businesses which are instrumental in the grown and creation of new processes and cures. The strong regulation promotes attitudes in research leading to the approval of the drugs and new therapy and care enabling fast market introduction of the treatments. In addition, the heightened incidence of genetic disorders along with the dint in personalization in the medical sector highly boosts the need for precise products thereby fueling the growth of the market.
• The time has come to strengthen North America’s position in the antisense and RNAi therapeutics market through correct academic-industry partnerships. This leads to a speedy combination of resources and sharing of knowledge in nurturing more vibrant avenues in developing new therapies. Furthermore, a large number of funds for research and development also point to further developments in this area, supported by both, the governments and companies. Not only does the region offer favorable conditions for carrying out antisense and RNAi therapeutics research, but it also enjoys increasing demand from the population and other clinicians for better and better treatment plans, for this reason, the region will dominate in the antisense and RNAi therapeutic development and commercialization and, thus, positively influence the results of disease treatments and the precise medicine system.

Active Key Players in the Antisense & RNAi Therapeutics Market

• GSK plc
• Olix Pharmaceuticals, Inc.
• Sanofi
• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma
• Benitec Biopharma Inc.
• Silence Therapeutics
• Ionis Pharmaceuticals, Inc
• Sarepta Therapeutics
• Percheron Therapeutics Limited
• Other Key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Antisense & RNAi Therapeutics Market by Indication
 4.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
 4.2 Antisense & RNAi Therapeutics Market Overview
 4.3 Oncology
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Oncology: Geographic Segmentation Analysis
 4.4 Cardiovascular Diseases
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Cardiovascular Diseases: Geographic Segmentation Analysis
 4.5 Respiratory Disorders
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Respiratory Disorders: Geographic Segmentation Analysis
 4.6 Neurological Disorders
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Neurological Disorders: Geographic Segmentation Analysis
 4.7 Infectious Diseases
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Infectious Diseases: Geographic Segmentation Analysis

Chapter 5: Antisense & RNAi Therapeutics Market by Technology
 5.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
 5.2 Antisense & RNAi Therapeutics Market Overview
 5.3 RNA Interference
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 RNA Interference: Geographic Segmentation Analysis
 5.4 Antisense RNA
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Antisense RNA: Geographic Segmentation Analysis

Chapter 6: Antisense & RNAi Therapeutics Market by Route of Administration
 6.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
 6.2 Antisense & RNAi Therapeutics Market Overview
 6.3 Pulmonary Delivery
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Pulmonary Delivery: Geographic Segmentation Analysis
 6.4 Intravenous Injections
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Intravenous Injections: Geographic Segmentation Analysis
 6.5 Intra-Dermal
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Intra-Dermal: Geographic Segmentation Analysis
 6.6 Intraperitoneal
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Intraperitoneal: Geographic Segmentation Analysis
 6.7 Topical
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Topical: Geographic Segmentation Analysis

Chapter 7: Antisense & RNAi Therapeutics Market by End Users
 7.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
 7.2 Antisense & RNAi Therapeutics Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Geographic Segmentation Analysis
 7.4 Specialty Clinics
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Specialty Clinics: Geographic Segmentation Analysis

Chapter 8: Antisense & RNAi Therapeutics Market by Distribution Channel
 8.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
 8.2 Antisense & RNAi Therapeutics Market Overview
 8.3 Hospital Pharmacy
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Hospital Pharmacy: Geographic Segmentation Analysis
 8.4 Retail Pharmacy
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Retail Pharmacy: Geographic Segmentation Analysis

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Benchmarking
  9.1.2 Antisense & RNAi Therapeutics Market Share by Manufacturer (2023)
  9.1.3 Industry BCG Matrix
  9.1.4 Heat Map Analysis
  9.1.5 Mergers and Acquisitions
  
 9.2 OLIX PHARMACEUTICALS
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Role of the Company in the Market
  9.2.5 Sustainability and Social Responsibility
  9.2.6 Operating Business Segments
  9.2.7 Product Portfolio
  9.2.8 Business Performance
  9.2.9 Key Strategic Moves and Recent Developments
  9.2.10 SWOT Analysis
 9.3 INC GSK PLC
 9.4 SANOFI
 9.5 ALNYLAM PHARMACEUTICALS
 9.6 INC
 9.7 IONIS PHARMACEUTICALS
 9.8 INC
 9.9 BENITEC BIOPHARMA INC
 9.10 SILENCE THERAPEUTICS
 9.11 ARBUTUS BIOPHARMA
 9.12 SAREPTA THERAPEUTICS
 9.13 INC
 9.14 PERCHERON THERAPEUTICS LIMITED
 9.15 OTHER ACTIVE PLAYERS

Chapter 10: Global Antisense & RNAi Therapeutics Market By Region
 10.1 Overview
 10.2. North America Antisense & RNAi Therapeutics Market
  10.2.1 Key Market Trends, Growth Factors and Opportunities
  10.2.2 Top Key Companies
  10.2.3 Historic and Forecasted Market Size by Segments
  10.2.4 Historic and Forecasted Market Size By Indication
  10.2.4.1 Oncology
  10.2.4.2 Cardiovascular Diseases
  10.2.4.3 Respiratory Disorders
  10.2.4.4 Neurological Disorders
  10.2.4.5 Infectious Diseases
  10.2.5 Historic and Forecasted Market Size By Technology
  10.2.5.1 RNA Interference
  10.2.5.2 Antisense RNA
  10.2.6 Historic and Forecasted Market Size By Route of Administration
  10.2.6.1 Pulmonary Delivery
  10.2.6.2 Intravenous Injections
  10.2.6.3 Intra-Dermal
  10.2.6.4 Intraperitoneal
  10.2.6.5 Topical
  10.2.7 Historic and Forecasted Market Size By End Users
  10.2.7.1 Hospitals
  10.2.7.2 Specialty Clinics
  10.2.8 Historic and Forecasted Market Size By Distribution Channel
  10.2.8.1 Hospital Pharmacy
  10.2.8.2 Retail Pharmacy
  10.2.9 Historic and Forecast Market Size by Country
  10.2.9.1 US
  10.2.9.2 Canada
  10.2.9.3 Mexico
 10.3. Eastern Europe Antisense & RNAi Therapeutics Market
  10.3.1 Key Market Trends, Growth Factors and Opportunities
  10.3.2 Top Key Companies
  10.3.3 Historic and Forecasted Market Size by Segments
  10.3.4 Historic and Forecasted Market Size By Indication
  10.3.4.1 Oncology
  10.3.4.2 Cardiovascular Diseases
  10.3.4.3 Respiratory Disorders
  10.3.4.4 Neurological Disorders
  10.3.4.5 Infectious Diseases
  10.3.5 Historic and Forecasted Market Size By Technology
  10.3.5.1 RNA Interference
  10.3.5.2 Antisense RNA
  10.3.6 Historic and Forecasted Market Size By Route of Administration
  10.3.6.1 Pulmonary Delivery
  10.3.6.2 Intravenous Injections
  10.3.6.3 Intra-Dermal
  10.3.6.4 Intraperitoneal
  10.3.6.5 Topical
  10.3.7 Historic and Forecasted Market Size By End Users
  10.3.7.1 Hospitals
  10.3.7.2 Specialty Clinics
  10.3.8 Historic and Forecasted Market Size By Distribution Channel
  10.3.8.1 Hospital Pharmacy
  10.3.8.2 Retail Pharmacy
  10.3.9 Historic and Forecast Market Size by Country
  10.3.9.1 Bulgaria
  10.3.9.2 The Czech Republic
  10.3.9.3 Hungary
  10.3.9.4 Poland
  10.3.9.5 Romania
  10.3.9.6 Rest of Eastern Europe
 10.4. Western Europe Antisense & RNAi Therapeutics Market
  10.4.1 Key Market Trends, Growth Factors and Opportunities
  10.4.2 Top Key Companies
  10.4.3 Historic and Forecasted Market Size by Segments
  10.4.4 Historic and Forecasted Market Size By Indication
  10.4.4.1 Oncology
  10.4.4.2 Cardiovascular Diseases
  10.4.4.3 Respiratory Disorders
  10.4.4.4 Neurological Disorders
  10.4.4.5 Infectious Diseases
  10.4.5 Historic and Forecasted Market Size By Technology
  10.4.5.1 RNA Interference
  10.4.5.2 Antisense RNA
  10.4.6 Historic and Forecasted Market Size By Route of Administration
  10.4.6.1 Pulmonary Delivery
  10.4.6.2 Intravenous Injections
  10.4.6.3 Intra-Dermal
  10.4.6.4 Intraperitoneal
  10.4.6.5 Topical
  10.4.7 Historic and Forecasted Market Size By End Users
  10.4.7.1 Hospitals
  10.4.7.2 Specialty Clinics
  10.4.8 Historic and Forecasted Market Size By Distribution Channel
  10.4.8.1 Hospital Pharmacy
  10.4.8.2 Retail Pharmacy
  10.4.9 Historic and Forecast Market Size by Country
  10.4.9.1 Germany
  10.4.9.2 UK
  10.4.9.3 France
  10.4.9.4 Netherlands
  10.4.9.5 Italy
  10.4.9.6 Russia
  10.4.9.7 Spain
  10.4.9.8 Rest of Western Europe
 10.5. Asia Pacific Antisense & RNAi Therapeutics Market
  10.5.1 Key Market Trends, Growth Factors and Opportunities
  10.5.2 Top Key Companies
  10.5.3 Historic and Forecasted Market Size by Segments
  10.5.4 Historic and Forecasted Market Size By Indication
  10.5.4.1 Oncology
  10.5.4.2 Cardiovascular Diseases
  10.5.4.3 Respiratory Disorders
  10.5.4.4 Neurological Disorders
  10.5.4.5 Infectious Diseases
  10.5.5 Historic and Forecasted Market Size By Technology
  10.5.5.1 RNA Interference
  10.5.5.2 Antisense RNA
  10.5.6 Historic and Forecasted Market Size By Route of Administration
  10.5.6.1 Pulmonary Delivery
  10.5.6.2 Intravenous Injections
  10.5.6.3 Intra-Dermal
  10.5.6.4 Intraperitoneal
  10.5.6.5 Topical
  10.5.7 Historic and Forecasted Market Size By End Users
  10.5.7.1 Hospitals
  10.5.7.2 Specialty Clinics
  10.5.8 Historic and Forecasted Market Size By Distribution Channel
  10.5.8.1 Hospital Pharmacy
  10.5.8.2 Retail Pharmacy
  10.5.9 Historic and Forecast Market Size by Country
  10.5.9.1 China
  10.5.9.2 India
  10.5.9.3 Japan
  10.5.9.4 South Korea
  10.5.9.5 Malaysia
  10.5.9.6 Thailand
  10.5.9.7 Vietnam
  10.5.9.8 The Philippines
  10.5.9.9 Australia
  10.5.9.10 New Zealand
  10.5.9.11 Rest of APAC
 10.6. Middle East & Africa Antisense & RNAi Therapeutics Market
  10.6.1 Key Market Trends, Growth Factors and Opportunities
  10.6.2 Top Key Companies
  10.6.3 Historic and Forecasted Market Size by Segments
  10.6.4 Historic and Forecasted Market Size By Indication
  10.6.4.1 Oncology
  10.6.4.2 Cardiovascular Diseases
  10.6.4.3 Respiratory Disorders
  10.6.4.4 Neurological Disorders
  10.6.4.5 Infectious Diseases
  10.6.5 Historic and Forecasted Market Size By Technology
  10.6.5.1 RNA Interference
  10.6.5.2 Antisense RNA
  10.6.6 Historic and Forecasted Market Size By Route of Administration
  10.6.6.1 Pulmonary Delivery
  10.6.6.2 Intravenous Injections
  10.6.6.3 Intra-Dermal
  10.6.6.4 Intraperitoneal
  10.6.6.5 Topical
  10.6.7 Historic and Forecasted Market Size By End Users
  10.6.7.1 Hospitals
  10.6.7.2 Specialty Clinics
  10.6.8 Historic and Forecasted Market Size By Distribution Channel
  10.6.8.1 Hospital Pharmacy
  10.6.8.2 Retail Pharmacy
  10.6.9 Historic and Forecast Market Size by Country
  10.6.9.1 Turkey
  10.6.9.2 Bahrain
  10.6.9.3 Kuwait
  10.6.9.4 Saudi Arabia
  10.6.9.5 Qatar
  10.6.9.6 UAE
  10.6.9.7 Israel
  10.6.9.8 South Africa
 10.7. South America Antisense & RNAi Therapeutics Market
  10.7.1 Key Market Trends, Growth Factors and Opportunities
  10.7.2 Top Key Companies
  10.7.3 Historic and Forecasted Market Size by Segments
  10.7.4 Historic and Forecasted Market Size By Indication
  10.7.4.1 Oncology
  10.7.4.2 Cardiovascular Diseases
  10.7.4.3 Respiratory Disorders
  10.7.4.4 Neurological Disorders
  10.7.4.5 Infectious Diseases
  10.7.5 Historic and Forecasted Market Size By Technology
  10.7.5.1 RNA Interference
  10.7.5.2 Antisense RNA
  10.7.6 Historic and Forecasted Market Size By Route of Administration
  10.7.6.1 Pulmonary Delivery
  10.7.6.2 Intravenous Injections
  10.7.6.3 Intra-Dermal
  10.7.6.4 Intraperitoneal
  10.7.6.5 Topical
  10.7.7 Historic and Forecasted Market Size By End Users
  10.7.7.1 Hospitals
  10.7.7.2 Specialty Clinics
  10.7.8 Historic and Forecasted Market Size By Distribution Channel
  10.7.8.1 Hospital Pharmacy
  10.7.8.2 Retail Pharmacy
  10.7.9 Historic and Forecast Market Size by Country
  10.7.9.1 Brazil
  10.7.9.2 Argentina
  10.7.9.3 Rest of SA

Chapter 11 Analyst Viewpoint and Conclusion
11.1 Recommendations and Concluding Analysis
11.2 Potential Market Strategies

Chapter 12 Research Methodology
12.1 Research Process
12.2 Primary Research
12.3 Secondary Research